Agenix Discloses Plans for Clinical Trial of Hepatitis B Drug
6/8/2011 12:02:30 PM
June 9, 2011 -- Agenix released a long-lead schedule for China approval of its new treatment for hepatitis B, AGX-1009. If everything goes according to plan, the company will apply in Q2 of 2012 to begin clinical trials of the drug. The trials themselves could start as early as late 2012. Agenix is developing the drug in partnership with the Institute of Medicinal Biotechnology (IMB), located in Beijing, a division of the Chinese Academy of Medical Sciences. More details....
Stock Symbol: (ASX: AGX)